PainTEQ

Executive Summary

PainTEQ is a privately held medical device company based in Tampa, Florida, dedicated to addressing sacroiliac (SI) joint pain through its proprietary LinQ minimally invasive stabilization procedure. Founded in 2015, the company aims to improve patient quality of life by offering a less invasive alternative to traditional SI joint fusion surgeries. The LinQ procedure utilizes a unique implant design to stabilize the joint while preserving natural anatomy, potentially reducing recovery time and complications. PainTEQ is still in an early commercial or pre-commercial stage, with limited public information on funding or revenues. The company's innovative approach targets a significant unmet need, as SI joint pain affects millions and is often underdiagnosed. However, given its private status, the company faces challenges in scalability, regulatory approvals, and market adoption against established competitors like SI-BONE. The future success hinges on clinical evidence, surgeon adoption, and reimbursement coverage.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance or expanded indication for LinQ60% success
• Q3 2026Publication of pivotal clinical study results50% success
• Q3 2026Strategic partnership or distribution agreement40% success